Daniel Scherer retweeted
🎉 We are beyond excited to unveil our latest major content release and new mobile app! 🎉
The content release includes an extensive update to the Rheumatology and Palliative Care guidelines. There's also a significant update to the Toxicology and Toxicology guidelines, plus more than 100 additional updates across other guidelines. We've also just launched a mobile app to support more frequent content updates and modernise authentication processes. Explore the updates now 👉 bit.ly/3ZIN2fm
#ContentRelease #Updates #NewApp #AustralianGuidelines #Healthcare
Daniel Scherer retweeted
BREAKING NEWS
The 2024 #NobelPrize in Physiology or Medicine has been awarded to Victor Ambros and Gary Ruvkun for the discovery of microRNA and its role in post-transcriptional gene regulation.
HELIOS-B: Novel ‘silencer’ agent reduces Death & CV Events in ATTR-CM, with efficacy both in patients on monotherapy and ~ 40% of study population on Tafamidis #ESCCongress2024
1
105
Daniel Scherer retweeted
#Anticoagulants cause bleeding without preventing #stroke in patients with atrial high rate episodes (AHRE), but without ECG-diagnosed #Afib ⬇️
#ESCCongress NOAH-AFNET 6 trial #AHRE
Daniel Scherer retweeted
While you're listening we'd love you to complete our statin use survey: apcmc.qualtrics.com/jfe/form…
We have 3 Amazon gift cards up for grabs and by filling in the survey you can go in the draw to win one!
Daniel Scherer retweeted
The REVIVED study (Percutaneous Revascularisation for Ischaemic Ventricular Dysfunction) demonstrating that patients with ischaemic cardiomyopathy continue to have high rates of mortality and hospitalisation for HF even with contemporary medical and device therapy.
Daniel Scherer retweeted
#SECURE trial: polypill containing aspirin, atorvastatin and ramipril leads to clinically relevant reductions in recurrent #cardiovascular events in post-myocardial infarction patients.
#ESCCongress
Daniel Scherer retweeted
A polypill strategy in secondary prevention: the SECURE trial shows that a treatment strategy based on a polypill containing aspirin, atorvastatin and ramipril led to fewer recurrent CV events following Myocardial Infarction - presumably due to improved adherence
Daniel Scherer retweeted
Calling all doctors! We'd like to elucidate the differences in statin usage across the Asia Pacific region. If you have a spare 5-10 minutes please complete our survey! You can access it at our website. 📝
apcmc.net/what-we-do/project…
Daniel Scherer retweeted
Our article, a state-of-the-art review on Polygenic Risk Scores for Atherosclerotic cardiovascular disease in Asia-Pacific is in the latest issue of #JACCAsia
Check it out here: https://nitter.cf/t.co/C1XXhtEwZU
Daniel Scherer retweeted
Missed our ESC Clinical Trial Forum this week? Don't worry - all of the sessions are now live for viewing on our website! Enjoy!
e2p.com.au/e2p_sahmri_event/…
Our most recent work with The APCMC looking at cardiometabolic risk in the Asia Pacific region
Check out our latest paper published in The American Journal of Preventive Cardiology on Tackling cardiometabolic risk in the Asia Pacific region!!
doi.org/10.1016/j.ajpc.2020.…
5
Daniel Scherer retweeted
The publication section on our website provides links to all of our recent publications.
Our most recent article; Statin intolerance: an updated, narrative review mainly focusing on muscle adverse effects can be downloaded here:
apcmc.net/publication/statin…
Daniel Scherer retweeted
Check out our Webinar on Key Studies from the ESC 2020! Streaming from the APSC Cloud via YouTube and Facebook on the 24th of October.
“Australians are smart people, they are common sense people...we rely on their judgement as well."
Scott Morrison 15/3/20
1
4
We know we have a limited supply of reagent to perform the PCR required for Covid-19 testing in Australia and that undertesting in other countries has likely contributed to spread of coronavirus.
Great to see the NRL doing their bit for the greater good of the community 🤦♂️
It’s always a good time to reassess what your health insurers are providing you and consider whether they act in your best interests or theirs.
What NIB are attempting to do is one of the main reasons clinicians were so worried about My Health Record
theaustralian.com.au/nation/…
1
Daniel Scherer retweeted
Sorry for my tardiness, but here is a brief summary of AHA Lp(a) highlights:
1- elevated Lp(a) is associated with reduced overall longevity
2- In Odyssey outcomes, elevated Lp(a) was associated with both peripheral arterial disease (PAD) and deep venous thrombosis (mainly PAD)
Great to see high impact research like this being lead from Adelaide
RCT of a 0/1-hour hs-cTnT protocol for suspected ACS demonstrates a <1% 30-day death or MI rate with early discharge ow.ly/IBc850vJUOA #CIRCESC19 #AHAJournals @FlindersHeart @AHAScience
6





















